SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?


To: sense who wrote (174527)7/9/2021 6:33:41 PM
From: TobagoJack  Read Replies (1) | Respond to of 217669
 
I wonder if CoVid 2021-2022 is priced-in



To: sense who wrote (174527)7/10/2021 1:54:36 PM
From: carranza21 Recommendation

Recommended By
Haim R. Branisteanu

  Read Replies (2) | Respond to of 217669
 
The data shows that over 99% of deaths from new cases takes place among unvaccinated patients.

If you are unvaccinated and have a medical issue, you are taking foolish and unnecessary risks.

It is that simple.



To: sense who wrote (174527)7/10/2021 6:04:13 PM
From: TobagoJack  Read Replies (1) | Respond to of 217669
 
Re <<Delta>>

... rising, and data is not indicating anything tame. Should current trend continue for 30 days duration, the situation phase-changes from within-expectation to too-late-dire, like it happened in Wuhan when folks thought Covid a usual flu.

Maybe perhaps possibly could-be that vaccination helps the situation. Must flow the script day-by-day now. Kids school shall open soon. Moving the cursor on the graph that pops up on search term is telling, that we hope the conclusion after 30-days from today is comforting, else nothing bad priced-in



I find the second death case odd as in unusual, not because of CoVid, but am agnostic and pro-choice w/r to marriage.

haaretz.com

COVID in Israel: Serious Cases Double in a Week as Delta Variant Spreads

The first case of the COVID-19 delta plus variant in Israel was diagnosed on Wednesday

The number of serious coronavirus cases in Israel has almost doubled in the past week and is now standing at 46, according to data released by the Health Ministry on Thursday.

In addition, Israel reported 518 new COVID-19 cases on Wednesday, raising the number of active cases to 3,568. The death toll from the virus now stands at 6,429.

Out of the 74,421 coronavirus tests conducted on Wednesday, 0.7 percent came back positive.

Two COVID patients died in Israel on Wednesday night. One was an unvaccinated 48-year-old man. He died at Wolfson Medical Center in Holon. His doctors said that he was transferred from a different hospital and was on a ventilator before he succumbed to the illness. They added that he didn't suffer from any preexisting conditions.

The other COVID patient, a 46-year-old man, died at Rambam Hospital in Haifa. He was fully vaccinated against the virus. His wife, who is 70-year-old, is also hospitalized in a moderate condition after catching the virus.

Also on Wednesday, the Israeli Health Ministry reported that a vaccinated passenger who had arrived in Israel from abroad was diagnosed with the country's first case of a new coronavirus variant known as delta plus.

Another person, who came into contact with the carrier, currently awaits his COVID-19 test result.

Israel recommends vaccinating 12 to 15-year-olds amid Indian COVID strain fears
COVID in Israel: The case for masks — even if you're vaccinated COVID infections in Israel reach another peak as delta wave continues

While the delta plus variant seems to be similar to the widespread delta variant, it is still unclear whether it is more contagious or dangerous than the delta variant. The delta plus variant is different in its spike protein on the surface of the virus, which enables the virus to bind to a cell and infect it.

The coronavirus cabinet decided Wednesday that all passengers arriving in Israel will be required to go into quarantine, even if they have been vaccinated in Israel, until they receive a negative COVID-19 test taken upon arrival. The new restrictions will go into effect in the coming days.

The delta plus variant was first discovered in India, as was the delta variant, and has now been found in a number of other countries, including the United States and Britain. It is not apparent, however, whether it will become the dominant strain in those countries.



To: sense who wrote (174527)7/10/2021 7:25:02 PM
From: TobagoJack  Read Replies (1) | Respond to of 217669
 
Re <<Or... it says "something else" is making the Delta variant have a greater impact in one place, or in one group of people, more than in another...?>>

True, especially as variant Delta seems to be breaching the vaccination ramparts everywhere where masking is socially not-mandatory and legally permitted.

As at this moment we in HK must be masked when in public space (including beach whilst not swimming) and transport (including taxi), and are limited to 4 per table unless in private room of restaurants, vaccination voluntary, either BioNTech-Fosun (same as BioNTech-Pfizer) or Coronvac by SinoPharm

Vaccine-hesitancy is high, and incidence of infection is very low. Economy is more open than not but per new-normal, and tourism is way way way down.

Note that we are being bombarded with FUD per USA MSM weaponisation re vaccination flavours even as we are cognisant that vaccination around the world failing irrespective of flavours, and so we 'wait for it' agnostic as opposed to do anything more active than we already are, iow, just be careful, alert, and agile.

First sign of trouble, depending on nature of trouble, rush one or the other way, per battlefield









cnbc.com

Six vaccinated countries have high Covid infection rates. Five of them rely on Chinese vaccines
Yen Nee Lee


Covid-19 vaccines by Chinese firms Sinopharm (left) and Sinovac arrived at the Phnom Penh International Airport in Cambodia on June 8, 2021.

Sovannara | Xinhua News Agency | Getty Images

Among countries with both high vaccination rates and high rates of Covid-19 infection, most rely on vaccines made in China, a CNBC analysis shows.

The findings come as the efficacy of Chinese vaccines faces growing scrutiny, compounded by a lack of data on their protection against the more transmissible delta variant. CNBC found that weekly Covid cases, adjusted for population, have remained elevated in at least six of the world’s most inoculated countries — and five of them rely on vaccines from China.

CNBC identified 36 countries with more than 1,000 weekly new confirmed cases per million people as of July 6, using figures from Our World in Data, which compiles information from sources including the World Health Organization, governments and researchers at the University of Oxford. CNBC then identified countries among those 36 where more than 60% of the population has received at least one dose of Covid vaccine.

Those countries numbered six, and five of them use Chinese vaccines as a significant part of their national inoculation programs: United Arab Emirates, Seychelles, Mongolia, Uruguay and Chile. The one country among them that doesn’t depend on Chinese vaccines is the United Kingdom.

Mongolian state-owned news agency Montsame reported in May that the country has received 2.3 million doses of vaccine by China’s state-owned Sinopharm. That far exceeds the 80,000 doses of Russia’s Sputnik V and around 255,000 doses of Pfizer-BioNTech shot that Mongolia received as of last week.

Chile administered 16.8 million doses of vaccines from Beijing-based Sinovac Biotech — compared with 3.9 million doses of Pfizer-BioNTech and smaller amounts of two other vaccines, Reuters reported last month.

The UAE and Seychelles depended heavily on the Sinopharm vaccine at beginning of their inoculation campaigns, but each has more recently introduced other vaccines. In Uruguay, Sinovac’s shot is one of the two most-used vaccines, alongside Pfizer-BioNTech’s.

Meanwhile, the United Kingdom has approved vaccines by Moderna, AstraZeneca-Oxford, Pfizer-BioNTech and Janssen. U.K. Covid cases have spiked in recent weeks as the more transmissible delta variant has spread there.

Sinopharm and Sinovac did not respond to CNBC requests for comment.

Several factors can cause a surge in Covid cases in countries with high vaccination rates. Vaccines don’t offer 100% protection, so those who are inoculated can still be infected. At the same time, new variants of the coronavirus could prove better at overcoming vaccines.

The best option for many countries
Countries should not stop using Covid-19 vaccines from China, epidemiologists say, especially while the supply of vaccines is limited among low- and middle-income nations.

Many of the countries and territories that approved vaccines by Sinopharm and Sinovac are developing nations that can’t compete with wealthier countries for vaccines developed in the United States and Europe.

Ben Cowling, a professor at The University of Hong Kong’s School of Public Health, said countries may decide to use certain vaccines depending on their long-term objectives.

“Some countries may accept a low level of circulation as long as there are relatively few severe cases and deaths from COVID-19,” Cowling, who heads the school’s epidemiology and biostatistics division, told CNBC in an email. “That should be achievable with high coverage of any of the available vaccines.”

Still, some countries are steering clear of China’s vaccines. Costa Rica last month rejected a delivery of vaccines developed by Sinovac after concluding it isn’t effective enough.

WHO approval
The World Health Organization approved vaccines from Sinopharm and Sinovac for emergency use.

The effectiveness of the two Chinese vaccines is lower than that of Pfizer- BioNTech and Moderna, both of which have shown more than 90% efficacy.

Sinopharm’s vaccine has an efficacy of 79% against symptomatic Covid infections, the WHO says, but its effectiveness among certain groups — such as people 60 and older — isn’t clear. The efficacy of Sinovac’s shot has come in at around 50% to higher than 80%, depending on the country where trials were held.

Experts say findings between clinical trials can’t be compared directly, because each trial is set up differently. But a Hong Kong study found “substantially higher” antibody levels in people that received the BioNTech shot, compared with those who got the Sinovac vaccine, the South China Morning Post reported.

Some experts suggest that the technology behind the different Covid vaccines could explain variations in their effectiveness.

Sinopharm and Sinovac’s vaccines trigger an immune response by exposing the body to a weakened or “inactivated” virus — a tried and tested method that has been used by vaccines for decades. Pfizer-BioNTech and Moderna based their vaccines on a technology called messenger RNA, which instructs the body to make viral proteins that induce an immune response.

CNBC Health & Science
Read CNBC’s latest global coverage of the Covid pandemic:

Here’s what you need to know about the lambda Covid variant

New Covid outbreaks a top risk to economic recovery, OECD chief says

Pfizer says it is developing a Covid booster shot to target the highly transmissible delta variant

Americans will need masks indoors as U.S. heads for ‘dangerous fall’ with surge in delta Covid cases

“Inactivated vaccines are easy to manufacture and are known for their safety, but tend to produce a weaker immune response compared to some other vaccine types,” Michael Head, senior research fellow in global health at the University of Southampton in the U.K., wrote in an article published on The Conversation website.

Still, large phase three clinical trials showed that inactivated vaccines have “high efficacy against severe disease and death” from Covid, said Cowling.

The professor told CNBC that the spikes in Covid cases among some countries that use Chinese vaccines “tend to be surges in mild infections with very few severe cases in fully vaccinated individuals.”

‘Herd immunity’
When vaccines have lower efficacy, more people need to be inoculated to reach “herd immunity.” That happens when the virus no longer transmits rapidly because most people are immune from having been vaccinated or having recovered from an infection.

Some countries decided to try to achieve herd immunity early in the pandemic, but no countries are known to have succeeded. Some that said they would reach herd immunity, such as Sweden, wound up being hit much harder by Covid than neighboring countries that went the vaccination route.

A study the University of New South Wales’s Kirby Institute in Sydney claimed that in the Australian state of New South Wales, herd immunity could be achieved if 66% of the population received vaccines with 90% efficacy against all infection.

The proportion of the population that needs to be vaccinated rises to 86% if the vaccine efficacy is 70%, and herd immunity is not achievable if the vaccine efficacy is below 60%, the study showed.